Chris Heberlig

Chief Financial Officer at KSQ Therapeutics

Chris Heberlig joined KSQ with over 20 years of experience managing and leading teams, including overseeing the financial and operational responsibilities of private and publicly traded biotechnology companies. Before his role at KSQ, Chris served as Chief Financial Officer of Kiniksa Pharmaceuticals, where he was part of the company’s founding team and in-licensed a portfolio of products. During his time at Kiniksa, he oversaw three private financing rounds, an initial public offering, and a follow-on financing as part of developing and advancing the company’s portfolio of programs. Prior to Kiniksa, Chris was at Synageva BioPharma Corp., where he held roles in global financial and operational leadership, most recently serving as Senior Vice President of Finance and Business Operations and Chief Accounting Officer. At Synageva, Chris also oversaw the company’s transition to the public markets and significant organizational growth. Earlier in his career, he held financial leadership positions at Panacos Pharmaceuticals Inc. and EPIX Pharmaceuticals Inc., both publicly traded biotechnology companies. He received an MBA from Boston University and a BA in economics from St. Lawrence University. He is also a Certified Public Accountant

Links

Previous companies

Kiniksa Pharmaceuticals logo
PwC logo

Timeline

  • Chief Financial Officer

    May, 2021 - present